Gaceta sanitaria
-
Randomized Controlled Trial Multicenter Study Clinical Trial
[Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
The PROWESS clinical trial has shown that treatment with drotrecogin alpha (activated) in patients with severe sepsis is associated with a reduction in the absolute risk of death compared with standard treatment. The aim of the present study was to assess the cost-effectiveness of drotrecogin alpha (activated) versus that of standard care in the treatment of severe sepsis in Spain. ⋯ Treatment with drotrecogin alfa (activated) presents a favorable cost-effectiveness ratio compared with other health care interventions commonly used in Spain.